What does it take to hack cancer? Members of Bristol-Myers Squibb’s U.S. Medical team are hoping a new agreement with the Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) will help unlock the answer.
Earlier this week, Bristol-Myers Squibb announced a multi-year research collaboration with the two organizations aimed at advancing immuno-oncology research. In reaching the agreement, Bristol-Myers Squibb becomes the first industry partner to collaborate with CRI and PICI (pronounced pie-sea), which was formed last April with a $250M grant from billionaire tech entrepreneur Sean Parker.
Parker established PICI as a novel collaboration model to bring together industry, academic and philanthropic participants with a shared goal of accelerating immunotherapy research to develop and deliver new treatment options to cancer patients.
Because of PICI’s roots in Silicon Valley, #hackcancer has become a sort of rallying cry in describing Parker’s efforts to fight the deadly disease. It’s tech speak for disrupting or bringing a new approach to a problem. Whichever way one chooses to describe it, this latest agreement is aimed at bringing speed, collaboration and innovation to the fight against cancer.